Proof of Confidence Study of CCR2 Antagonist (BMS-741672) in Insulin Resistance

• Status: Completed
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to determine whether a CCR2 antagonist (BMS-741672) improves glucose homeostasis in drug-naive type 2 diabetic patients

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb

Criteria

Inclusion Criteria:

• Drug-naive Type 2 diabetics with a screening HbA1c of ≥ 7.5% and ≤ 10%

• Screening FPG ≥ 140 mg/dL and ≤ 220 mg/dL

• BMI ≤ 40 kg/m2

Exclusion Criteria:

• Active tuberculosis

• Symptoms of poorly controlled diabetes

• History of diabetic ketoacidosis

• Significant cardiovascular history or gastrointestinal disorders

• History of unstable or rapidly progressing renal disease

• Active liver disease and/or significant abnormal liver function

• Abnormal chest x-ray at screening indicative of tuberculosis or other infection